This company develops advanced tools at the intersection of microfluidic design and analytical excellence to simplify mass spectrometry sample preparation. Their platform addresses bottlenecks in biotherapeutic analysis by streamlining workflows for researchers. This technology enables scientists to accelerate discovery by removing technical barriers in sample processing.

Arima Genomics utilizes 3D genomics and Hi-C technology to provide detailed insights into the sequence, structure, and regulatory landscape of genomes, enabling the identification of novel biomarkers and therapeutic targets. Their solutions facilitate rapid genome assembly and analysis, addressing the need for comprehensive genomic characterization in cancer research and human health.

The startup develops HiDef-B8, an animal-free and serum-free growth medium that maintains induced pluripotent stem cells in a pluripotent state beyond standard passages. This formulation reduces the reliance on animal-derived lab reagents and lowers the costs associated with stem cell culture and cultivated meat production.

NanoCellect provides microfluidic cell sorters that operate below 2 psi to minimize shear stress and preserve cell viability. The platform uses disposable sterile cartridges, accepts native culture media without sheath fluid, and includes a touchscreen interface with single‑cell deposition into 96‑ or 384‑well plates for downstream assays.

Novoron is developing pharmaceutical therapies that target low-density lipoprotein receptors to enhance nerve regeneration in the central nervous system. Their approach aims to improve outcomes for conditions such as Alzheimer's disease, multiple sclerosis, and spinal cord injuries by restoring the brain's and spinal cord's natural regenerative capabilities.

Ola is a finance super app designed specifically for US Hispanics and Latinxs, providing tools for investment, savings, and financial planning. By addressing the significant gap in stock and cryptocurrency ownership among Latinx individuals, Ola empowers users to create personalized financial strategies and access high-yield investment accounts.

Potato AI develops an integrated platform that automates the generation, review, and execution of lab protocols using a deep semantic understanding of open-access literature. This technology enables research labs to streamline their workflows and focus on experimental innovation by reducing the time spent on protocol setup and troubleshooting.

Rybodyn utilizes proprietary RyboCypher™ technology to sequence and analyze the dark proteome, revealing previously overlooked therapeutic targets. This platform integrates novel RNA sequencing with AI models to predict proteins encoded by non-coding RNAs. The company translates these cryptic targets into a pipeline of antibody-based drug candidates for next-generation immunotherapies.